Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance-Reference-Cited by-同舟云学术

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

Published:2013-02-20 Issue:11 Volume:56 Page:1530-1538
ISSN:1537-6591
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Rijal Suman,Ostyn Bart,Uranw Surendra,Rai Keshav,Bhattarai Narayan Raj,Dorlo Thomas P. C.,Beijnen Jos H.,Vanaerschot Manu,Decuypere Saskia,Dhakal Subodh S.,Das Murari Lal,Karki Prahlad,Singh Rupa,Boelaert Marleen,Dujardin Jean-Claude

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/56/11/1530/17850819/cit102.pdf

Reference33 articles.

1. Leishmaniasis worldwide and global estimates of its incidence;Alvar;PLoS One,2012

2. Can visceral leishmaniasis be eliminated from Asia?;Joshi;J Vector Borne Dis,2008

3. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic;Sundar;Clin Infect Dis,2000

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Leishmania activity and molecular docking of unusual flavonoids-rich fraction from Arrabidaea brachypoda (Bignoniaceae);Molecular and Biochemical Parasitology;2024-09

2. Free Radical Production Induced by Nitroimidazole Compounds Lead to Cell Death in Leishmania infantum Amastigotes;Molecules;2024-08-26

3. Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1;PLOS Pathogens;2024-07-11

4. Evaluation of blood based quantitative PCR as a molecular diagnostic tool for post kala-azar dermal leishmaniasis (PKDL);Molecular Biology Reports;2024-06-01

5. Leishmania major MAPK4 intercepts and redirects CD40 signaling promoting infection;International Immunopharmacology;2024-06